iShares Biotechnology ETF
766 hedge funds and large institutions have $7.88B invested in iShares Biotechnology ETF in 2020 Q2 according to their latest regulatory filings, with 163 funds opening new positions, 257 increasing their positions, 198 reducing their positions, and 58 closing their positions.
181% more first-time investments, than exits
New positions opened: 163 | Existing positions closed: 58
71% more funds holding in top 10
Funds holding in top 10: 14 → 24 (+10)
55% more capital invested
Capital invested by funds: $5.09B → $7.88B (+$2.79B)
30% more repeat investments, than reductions
Existing positions increased: 257 | Existing positions reduced: 198
15% more funds holding
Funds holding: 666 → 766 (+100)
4.18% more ownership
Funds ownership: 79.73% → 83.91% (+4.2%)
22% less call options, than puts
Call options by funds: $700M | Put options by funds: $897M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$294M |
| 2 |
BNP Paribas Financial Markets
Paris,
France
|
+$236M |
| 3 |
JP Morgan Chase
New York
|
+$203M |
| 4 |
CM
Churchill Management
Los Angeles,
California
|
+$199M |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$79.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$158M |
| 2 |
Citigroup
New York
|
-$112M |
| 3 |
Barclays
London,
United Kingdom
|
-$58.8M |
| 4 |
Morgan Stanley
New York
|
-$44.6M |
| 5 |
Millennium Management
New York
|
-$29.7M |
IBB Hedge Fund Activity: Q2 2020 in Review
766 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in iShares Biotechnology ETF (IBB) for Q2 2020, worth a combined $7.88B — up 55% from $5.09B a quarter earlier.
Buyers outnumbered sellers: 163 funds opened new IBB positions and 58 closed out — a net gain of 105 holders — while 257 added to existing stakes and 198 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $294M. The largest seller was Bank of America, cutting an estimated $158M.
- 766 institutional investors held iShares Biotechnology ETF (IBB) as of Q2 2020, up from 666 in Q1 2020.
- Funds reported $7.88B of iShares Biotechnology ETF stock for Q2 2020, up 55% quarter-over-quarter.
- 163 funds opened new iShares Biotechnology ETF positions in Q2 2020 and 58 closed out, a net change of +105 holders.
- The largest iShares Biotechnology ETF buyer in Q2 2020 was Goldman Sachs, an estimated $294M added.
- The largest iShares Biotechnology ETF seller in Q2 2020 was Bank of America, an estimated $158M sold.
Based on aggregated 13F filings for Q2 2020.